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 There is increasing recognition of the value of pragmatic clinical trials, especially as it 
relates to the vision of a learning healthcare system that aims to closely integrate the delivery of 
medical services with clinical research. In such a system, the generation of knowledge would be 
³HPEHGGHGLQWRWKHFRUHRIWKHSUDFWLFHRIPHGLFLQH´OHDGLQJWR³FRQWLQXDOLPSURYHPHQWLQ
FDUH´1 The advent of a modern electronic health record system makes it feasible and relatively 
inexpensive to conduct studies in the context of routine clinical practice.2  Such a vision provides 
an opportunity to think creatively about novel trial designs that can fulfill this pragmatic 
imperative.   
,QWKLVSDSHUZHGHVFULEHDQHPHUJLQJSUDJPDWLFWULDOSDUDGLJPFDOOHGµ7ULDOVZLWKLQ
&RKRUWV¶7ZL&Vwhich involves longitudinal cohort studies that provide a platform for 
randomized clinical trials. To date, studies using the design have obtained research ethics 
committee approval in 10 countries (Australia, Canada, Finland, France, Germany, Mexico, 
Netherlands, Spain, UK and the USA) with the most growth in the UK,3-7 Canada,8-11 and the 
Netherlands.12  The rare disease SPIN (Scleroderma Patient-centered Intervention Network) 
cohort has obtained IRB approval to recruit to its cohort and conduct four intervention trials 
using the design in the US, Canada, Mexico, France and Spain.10 
We will first describe the features of TwiCs, and their strengths and limitations as a 
pragmatic randomized controlled trial (RCT) design. Because the TwiCs design is novel and 
unfamiliar to most research ethics committees/institutional review boards²and also because it 
involves an element of post-randomization consent which has a history of controversy{Flory 
2016}²we largely focus on the ethical issues in conducting TwiCs. We place TwiCs within a 
brief history of RCTs that obtain informed consent after randomization and then provide an 
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ethical analysis of TwiCs, including a discussion of how it might be regulated by US institutional 
review boards. 
Trials within Cohorts  
Randomised controlled trials remain the gold standard to prove effectiveness of 
interventions and this is no less true when the goal is to show the real-world effectiveness of the 
intervention in learning healthcare systems. However, the standard approach to RCTs is often 
complicated by slow recruitment rates, limited generalisability, limited long term follow up, and 
high costs. The µ7rials within CRKRUWV¶ design (formerly referred to as the 'cohort multiple RCT 
design'13,14) was created to address these problems.  
In the TwiCs design, a cohort of participants with the condition(s) of interest is recruited 
for a longitudinal cohort study.  At the time of recruitment into the cohort, the participants are 
given information about the process for their potential involvement in future intervention studies 
(i.e., TwiCs) and consent is obtained for potential future use of their data. As discussed below, 
there is some variation in how the design is operationalised. Although all obtain permission at 
the start WRXVHWKHFRKRUWV¶GDWDIRUIXWXUHVWXGLHVthe specificity of information and consent 
regarding future TwiCs varies among studies. Some have given no information regarding 
possible trial interventions to the cohort participants prior to any specific TwiC 4,15 while others 
obtain broad consent at initial recruitment into the cohort regarding future randomization prior to 
TwiCs and use of data in future TwiCs12,16 as described further below.  
After randomization to any given TwiC, additional consent to receive the intervention is 
obtained from participants who have been randomly assigned to the new intervention. Those 
assigned to the treatment as usual control arm do not provide any additional consent after 
randomization.   
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The TwiCs design has several advantages over standard RCT design. First, difficulty with 
recruitment is a common concern in RCTs. The TwiCs design takes advantage of the fact that 
recruitment into observational cohort studies is often easier and less selective. There is now 
evidence that recruitment for RCTs within such established cohorts can be highly efficient when 
compared to recruitment without such cohorts.17   
Second, disclosure of information and informed consent can be tailored to the needs of 
the participants (e.g., those not offered the new intervention are not burdened with information 
about the risks and potential benefits of trial intervention). Thus, the informed consent process is 
µSDWLHQWFHQWHUHG¶ DQGµUHDOZRUOG¶LQLWVJRDOV²replicating, as much as is ethically feasible, the 
real world routine health care where clinicians provide patients with the information they need, 
at the time they need it. As this approach avoids the selection bias introduced when recruitment 
and consent precedes randomization, it provides information on the acceptability of the 
intervention in the target population.  
Third, the design reduces some problems related to patient preferences in standard RCT 
designs. For instance, when a condition does not have highly effective interventions, the prospect 
of trying a new, if unproven, intervention is often an incentive for patients to enrol. In standard 
RCT designs, this often results in those randomized to the µtreatment as usual¶ arm dropping out 
or experiencing disappointment. But this does not occur in the TwiCs design.  
Another advantage of embedding an RCT within a cohort is that periodic research data 
collection that is part of the longitudinal study can provide outcome data in addition to data from 
medical records.10  Although the TwiCs design is useful for pragmatic studies, it has some 
limitations. Apart from identification of potential trial participants, the TwiCs design is not 
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useful for placebo controlled trials, trials ZLWKRXWµWUHDWPHQWDVXVXDO,¶ or when two commonly 
used treatments are to be tested in an RCT.   
A brief background on RCT designs with consent following randomization  
TwiCs is a descendent of a family of older proposals variously known DV³=HOHQGHVLJQ,´ 
³UDQGRPL]HGFRQVHQW,´RU³SUH-UDQGRPL]DWLRQ´designs.20 A brief history of these proposals and 
their implementation illustrates some of the strengths and weaknesses of trial designs that obtain 
consent for participation in an RCT after randomization. It also helps to clarify how TwiCs is 
different from earlier proposals.  
The original proposal for post-randomization consent, called a ³Zelen single-consent 
design,´ was the simplest: patients were, without prior consent or knowledge, randomized 
between ³EHVWVWDQGDUG´ care (usual care) and an intervention.20 Subjects assigned to the 
intervention were then asked for consent, while the others served as control subjects without 
their knowledge. Two types of advantages were proposed for the single-consent design. First, it 
reduces the need for patients to confront stressful aspects of research participation, such as 
knowing that their treatment is going to be randomly chosen and being denied access to an 
experimental treatment. Second, single-consent designs might increase the efficiency of accrual, 
in part because patients (assigned to the intervention arm) might be more inclined to enroll 
knowing that they were guaranteed to receive the intervention. 
Zelen seems to have interpreted the US Federal research regulations to say that as long as 
research subjects UHFHLYHGRQO\³established and accepted methods necessary to meet [their] 
needs´LQIRUPHGFRQVHQWZDVQRWQHFHVVDU\21 However, the Office of Protection from Research 
Risks (OPRR) disagreed. That office reprimanded the investigators of a study of neonates which 
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used a Zelen single consent design for failing to obtain consent from parents of the control group 
neonates.22  
&ULWLFLVPRIWKHVLQJOHFRQVHQWSURFHGXUHOHGWRJUHDWHULQWHUHVWLQWKHµGRXEOH-consent 
=HOHQGHVLJQ¶LQZKLFKERWKWKHXVXDOFDUHDQGLQWHUYHQWLRQDUPVDUHDSSURDFKHGIRUFRQVHQW,Q
double-consent, in contrast to single-consent, all participants are at least informed that they are 
participating in research. However, in addition to the obvious difference from a traditional RCT 
in obtaining consent after treatment assignment, Zelen double consent may include little or no 
information about the other arm of the trial, or indeed about the fact of randomization.18   
Trials using Zelen double and single consent designs have remained relatively 
uncommon²as of 2006, two reviews suggest that approximately 83 unique studies employing 
Zelen designs had been conducted.23,24 This relative unpopularity has no definitive explanation, 
but the experiences of investigators who have used post-randomization consent designs reveal 
both ethical and logistical problems. 
First, Zelen designs have attracted considerable ethical criticism.25 Even though patients 
assigned to the control group undergo no material harm, and might actually be spared burdens 
related to a traditional consent process, they might still reasonably expect to know that a new 
intervention is being tested for their condition and that they have been randomly assigned not to 
get the intervention. The perception that information is being withheld has been described as 
FDXVLQJDQµRXWFU\¶RIFRQFHUQDERXWWKHHWKLFVRIWKHHDUOLHVW=HOHQSURSRVDOVDQGVXEVHTXHQW
modifications have not fully allayed these concerns26,27.   As we note below, however, despite the 
1990 reprimand by the OPRR, pragmatic RCTs are beginning to be conducted in the U.S. with 
post-randomization single-consent procedures with the apparent knowledge of the Office of 
Human Research Protections (the successor to the OPRR).28 
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 Another problem with post-randomization consent is that it has not always proven to be 
as efficient as had been hoped.  Analysis of a post-randomization study has to be done as 
intention-to-treat, including patients who declined the intervention, which reduces study power.26  
Post-randomization designs must improve accrual and withdrawal rates sufficiently to make up 
for this loss of power; these improvements are difficult to predict and are not guaranteed. 21 27,29 
Ethics of informed consent for TwiCs and regulatory implications 
 As noted above, there are some variations in practice when it comes to the content of the 
initial consent procedures, at the time of enrolment into the cohort, regarding future embedded 
RCTs within the cohort. Thus, we will first describe what has been called a ³WZRVWDJH´ consent30 
which involves the greatest amount disclosure at the pre-randomization stage.  We then discuss 
other variations.  
 TwiCs with two stage consent (using pre-randomization broad consent about 
TwiCs).  In some jurisdictions, investigators implementing TwiCs have run into regulatory 
obstacles; this has led to the development of a µWZR-VWDJH¶FRQVHQW model.30  At the time of 
recruitment into the cohort, subjects will provide specific consent for the cohort study and also 
provide broad consent to randomizations for future TwiCs, for future contact if randomized to 
the intervention arm of TwiCs, and for use of their data in future TwiCs if randomized to the 
control arm.  This is the first stage of consent. 
For those whose data will serve as the control arm data, their participation in a TwiC is 
exhausted by two elements: (a) being randomly selected as a control and (b) use of their data 
(usually collected from clinical medical records, or in some cases, from measurements that are 
part of the longitudinal cohort study10) in the TwiC.  Despite these elements, the entirety of their 
clinical experience will be decided by what their physicians consider to be the best care for them. 
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And no additional research measures are needed specifically for TwiCs; thus no additional 
interactions or interventions of research are involved ZKHQWKHVHSHUVRQV¶GDWDDUHXVHGLQ
TwiCs.  In sum, persons in the control arm receive usual clinical care and will have given 
consent to every element of their research participation. 
The lack of specificity in broad consent (i.e., broad permission for future use without 
specific consent for each use) has led to some prominent controversies, such as the much 
publicized Havasupai case in which the controversy FHQWHUHGDURXQGUHVHDUFKHUV¶XVHRIVDPSOHs 
and data that went beyond the disease domains of initial focus of the research.31  The difference 
in the TwiCs context is that unlike in most biobank-based research, the cohorts are disease-based 
(or at risk of it) as are the trials within them; thus, given the specificity of the domain of research, 
WKHUHLVOLWWOHULVNRIYLRODWLQJDQ\VXEMHFW¶VQRQ-welfare interests such as their cultural, religious, 
and moral commitments.32  For instance, for a person in a diabetes cohort who provides broad 
consent for use of their electronic health record and other data for evaluation of future diabetes 
treatments, WKHUHLVOLWWOHGDQJHURISDWLHQWV¶QRQ-welfare interests (regarding the type of uses to 
which their data are put) being compromised.  (However, it should be noted that if a cohort of 
interest were a very general one²for example, one encompassing all patients in an integrated 
health delivery system²conducting TwiCs in such a cohort would require further ethical 
analysis regarding the content of the initial broad consent.) 
 Those randomized to the intervention arms of TwiCs will have given consent to be 
approached for enrolment in such trials (in the first stage broad consent). After randomization to 
a TwiC, they will then provide informed consent for the TwiC (second stage of consent). They 
would not be enrolled in a TwiC unless they explicitly give consent after they are provided all of 
usually required elements of informed consent for an RCT.  Thus, when both stages of consent 
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are taken into account, everyone who enrolls in the intervention arm of the TwiCs will have 
given informed consent to every aspect of their research participation in the TwiC. 
 TwiCs without pre-randomization broad consent.  Some TwiCs do not obtain explicit 
pre-randomization broad consent (covering the possibility of future randomization, future contact 
for intervention studies, and use of data specifically for TwiCs) and instead may obtain 
permission for unspecified future uses of their data (as part of the initial consent for enrolling in 
the cohort).4,10,15 The rationale is as follows.  For the intervention arm group of a future TwiC, 
when they are randomized into the intervention arm and then subsequently contacted to be asked 
if they wish to enroll in the TwiC, it is not that different from someone in a clinic being 
approached to participate in a traditional 5&77KHUHLVQRµFROGFRQWDFW¶LQYROYHGWKHVXEMHFWV
are aware that the clinic is a locus of clinical research, and they should not be surprised that they 
are being asked to consider participation in an RCT. 
 For the control arm, it might be argued that by enrolling in the cohort study (on, say, 
diabetes), their permission to the researchers to use their medical records and other data includes 
a variety of future research uses, such as for comparison purposes in a TwiC testing an 
intervention to treat diabetes.       
 It might be objected, however, that none of the study participants agreed to being 
randomized and thus are being used in a disrespectful way.  Is being merely randomized 
something for which consent is necessary, if one has already agreed WRKDYHRQH¶VGDWDXVHGin 
future research projects (as is the case for all who enrolled in the cohort)?  Consider a group of 
people who donate their tissues to a diabetes focused biobank so that the tissues can be used in 
future diabetes research. At a future date, a researcher selects a subsample sharing some trait, and 
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then randomizes them into two groups so that she can conduct a controlled laboratory experiment 
on the stored tissues. In this example, it does not seem that the donors are being disrespected. 
 There is another potential problem with TwiCs without pre-randomization broad consent.  
It is possible²indeed probable²that some persons who are enrolled in a cohort who later find 
out about TwiCs in that cohort may feel that the researchers could easily have obtained their pre-
UDQGRPL]DWLRQEURDGFRQVHQWIRUIXWXUH7ZL&VDQGPDGHWKHUHVHDUFKHUV¶SODQVIRUFRQGXFWLQJ
TwiCs in their cohort transparent from the beginning.  Some of these participants may feel that 
the researchers were not as transparent as they could have been, even while recognizing that the 
lack of transparency has no impact on their welfare (benefits and harms/burdens).  
 Different people will have different moral intuitions about whether pre-randomization 
broad consent for future TwiCs is ethically necessary. On one side of the argument is that there is 
a potential for mistrust due to the lack of transparency such that it may be not only ethically right 
but prudent to obtain that consent, especially if the burden of obtaining it is low. On the other 
side is the view that if a consent is not necessary and could cause confusion (since the idea of 
future randomization with asymmetric consequences for the participants, regarding future 
unspecified TwiC could be a challenging set of concepts to digest), then it may be better to avoid 
it.  We suspect that a part of the answer will rest on the particular features of the cohort and its 
TwiCs²the nature of the cohort, the interventions involved, and the setting in which the study is 
done and the reasonable expectations that researchers might anticipate in the participants.   
 Implications for US regulations?  Although the use of TwiCs is gaining momentum, 
most of the activity has been in countries outside the United States.  Given the potential 
advantages of the TwiCs design, it may prove useful for US researchers as well. However, the 
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regulations do differ among different jurisdictions, especially regarding the issue of when it is 
permissible to deviate from the traditional informed consent procedures. 
 How might IRBs apply the US research regulations to TwiCs?  The task for the IRBs will 
be different depending on whether cohort studies employ a two-stage consent (using pre-
randomization broad consent) for future TwiCs in that cohort.  We begin with the assumption 
that pre-randomization broad consent is used. 
First, unlike recent debates in US in which the focus has been on whether traditional 
informed consent is necessary for pragmatic trials in learning health systems,33,34 TwiCs does not 
need to rely on waivers or alterations of informed consent.  As noted above, the intervention arm 
participants, before consenting, would receive all of the information that persons enrolling in 
traditional RCTs would receive.  The only difference is that the information is given (and 
specific consent for TwiC obtained) after randomization while consent for the randomization 
would have been given separately at the time of enrolment into the cohort. 
 The FRQWURODUPSDUWLFLSDQWV¶FRQVHQWZRXOGQRWEHZDLYHGRUDOWHUHGHLWKHU7KH\ZRXOG
have provided informed consent for the cohort study, and also given broad consent for 
randomization and for the use of their data for TwiCs.  As already noted above, the pre-
randomization broad consent is ethically more robust than currently accepted consent standards 
for biobank research.  Since those are all of WKHµUHVHDUFKSDUWLFLSDWLRQ¶HOHPHQWVWKDWFRQWURO
groups are part of, and since they will have given consent to each element, there is no need to 
invoke the criteria for waiver or alteration of consent in the Common Rule.   
 What about TwiCs that are proposed without a substantive pre-randomization broad 
consent?  The regulatory situation could involve the IRBs requiring the investigator to show that 
the waiver or alteration criteria in the US regulations are met. As we saw above, the intuition 
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concerning the need for pre-randomization broad consent varies, and will likely vary among 
IRBs. It is quite possible that some IRBs will in fact see the lack of transparency regarding 
randomization and future TwiCs as implying at least an alteration of informed consent, and 
therefore will require that such a proposal meet the several regulatory criteria for waiver or 
alteration of informed consent in 45CFR46.116:  (a) the research must be minimal risk; (b) the 
research would be impracticable to conduct without the waiver or aOWHUDWLRQFWKHSDUWLFLSDQWV¶
rights or welfare would not be adversely affected by the waiver or alteration.  (d) The fourth 
condition of debriefing after the fact (which will not be further discussed here).   
 How might these criteria apply to studies that forgo substantive pre-randomization broad 
consent?  Although some TwiCs will be minimal risk, many will not be minimal risk; whether an 
IRB would or should analyze the risk-benefit issue separately for the intervention and the control 
arms is not clear.  In terms of the practicability of research criterion, it would be difficult to argue 
that a TwiC is impracticable if pre-randomization broad consent is used²especially since there 
are examples of cohorts with TwiCs that are being successfully conducted with pre-
randomization broad consent. And we have already noted that some people may see the lack of 
transparency about randomization into TwiCs as something that goes against their legitimate 
expectations²this could be interpreted by some as at odds with the condition that waiver or 
alteUDWLRQQRWDGYHUVHO\DIIHFWVXEMHFWV¶ULJKWVDQGZHOIDUH35  Thus, some IRBs could require the 
use of substantive pre-randomization broad consent for TwiCs.   
It is, however, possible that the specific circumstances of a cohort and a TwiC within it, 
may make the forgoing of pre-randomization broad consent justifiable under the criteria and 
therefore a case by case is still necessary. Of particular interest in this context is a pragmatic 
clinical trial in the US involving approximately 20,000 subjects comparing care management, 
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skills training, and treatment as usual for the prevention of suicide attempts among outpatients 
who endorse suicidal thoughts on a routine clinical measure.28  According to the investigators, 
this study uses a modified Zelen design (control arm patients are unaware of the RCT; subjects in 
the intervention arms provide clinical consent to the interventions) that has been approved by 
IRBs of multiple institutions, and WKHLQYHVWLJDWRUVUHSRUWKDYLQJKHOG³H[WHQVLYHGLVFXVVLRQV´
with the Office of Human Research Protections.  Thus, it appears that the study is deemed to 
pose no more than minimal incremental risk and also that it would have been impracticable to 
conduct without the waiver and alteration of consent, despite what amounts to a single-consent 
Zelen design.  
Conclusion 
For conditions in which longitudinal cohort studies can be valuable (which likely 
includes most chronic conditions), recruiting and conducting multiple randomized trials within 
such cohorts provide significant scientific and ethical advantages over both traditional and stand-
alone Zelen designs.  With the increasing emphasis on pragmatic trials,14,36 investigators from 
many countries are now using this design. One of the main obstacles to its use is the concern 
over the ethics of obtaining informed consent for the TwiC after randomizing the subjects and 
obtaining it only from the intervention arm. Pre-randomization consent to cohort participation as 
well as, in some cases, to more explicit broad consent to elements of future TwiCs (including for 
randomization, and use of data specifically for TwiCs) mitigates this ethical concern. However, 
regulatory policies vary among jurisdictions and interpretations of those policies vary among 
research ethics committees. Investigators who hope to benefit from the scientific and practical 
advantages of the TwiCs design will need to clearly articulate its ethical and scientific strengths 
and limitations. 
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